Table 1.
Selective down-regulation of CCR5 expression by lentiviral vector-mediated delivery of anti-CCR5 siRNA in human PBLs
| Donor | Treatment* | CCR5 expression
|
CXCR4 expression
|
||||
|---|---|---|---|---|---|---|---|
| % of CCR5+ cells in the GFP− population† | % of CCR5+ cells in the GFP+ population† | Fold of reduction‡ | % of CXCR4+ cells in the GFP− population† | % of CXCR4+ cells in the GFP+ population† | Fold of reduction‡ | ||
| A | Mock | 36.83 | N/A | 37.43 | N/A | ||
| FG12 | 43.03 | 27.96 | 37.07 | 46.38 | |||
| lacZ-siRNA | 50.20 | 25.36 | 33.94 | 49.24 | |||
| CCR5-siRNA | 42.87 | 3.63 | 6.99 | 39.95 | 52.22 | 0.94 | |
| B | Mock | 30.30 | N/A | 48.80 | N/A | ||
| FG12 | 41.62 | 29.00 | 39.68 | 47.09 | |||
| lacZ-siRNA | 35.48 | 32.63 | 45.44 | 47.64 | |||
| CCR5-siRNA | 49.16 | 3.38 | 9.65 | 31.27 | 51.30 | 0.93 | |
N/A, not applicable.
*
Lentiviral vector transduction was performed as described in Fig. 2. Eight days after the transduction, the cells were analyzed by FACS for the surface expression of CCR5 or CXCR4 (Materials and Methods).
†
Calculated from the quadrant percentage numbers from the CCR5 or CXCR4 vs. GFP FACS plots shown in Fig. 2.
‡
Expressed as the ratio of the percentage of CCR5+ or CXCR4+ cells scored in the GFP+ population between lacZ-siRNA and CCR5-siRNA [CCR5-siRNA(186)]-transduced samples.